A New Bliss Independence Model to Analyze Drug Combination Data
|
|
- Flora Shields
- 6 years ago
- Views:
Transcription
1 51867JBXXXX / Journal of Biomolecular ScreeningZhao et al. research-article014 Technical Note A New Bliss Independence Model to Analyze Drug Combination Data Journal of Biomolecular Screening 014, Vol. 19(5) Society for Laboratory Automation and Screening DOI: / jbx.sagepub.com Wei Zhao 1*, Kris Sachsenmeier 1*, Lanju Zhang, Erin Sult 1, Robert E. Hollingsworth 1, and Harry ang 1 Abstract The Bliss independence model is widely used to analyze drug combination data when screening for candidate drug combinations. The method compares the observed combination response ( O ) with the predicted combination response ( ), which was obtained based on the assumption that there is no effect from drug-drug interactions. Typically, the combination effect is declared synergistic if O is greater than. However, this method lacks statistical rigor because it does not take into account the variability of the response measures and can frequently cause false-positive claims. In this article, we introduce a two-stage response surface model to describe the drug interaction across all dose combinations tested. This new method enables robust statistical testing for synergism at any dose combination, thus reducing the risk of false positives. The use of the method is illustrated through an application describing statistically significant synergy regions for candidate drug combinations targeting epidermal growth factor receptor and the insulin-like growth factor 1 receptor. Keywords drug combination, drug screening, Bliss independence Introduction Various oncogenic cell signaling pathways are known to provide cross-talk and redundancy within tumors. 1 Thus, inhibition of such pathways individually by a single targeted therapy has been shown to lead to compensation by other pathways. This, in turn, results in a loss of sensitivity to the original targeted therapeutic agent at the cellular level. In the clinic, this type of compensation leads to innate and/or acquired tumor resistance and relapse. Because advanced tumors are often resistant to single agents, there is an increasing trend to combine drugs to achieve better treatment effect and reduce safety issues.,3 It is desirable that the combination drugs are synergistic; that is, better activity is achieved at lower dose levels when drugs are combined than individually observed at single drug doses. Depending on drug doses, drug combinations can yield activity that is synergistic, independent, or antagonistic. Commonly used statistical models to evaluate drug combination efficacy are the Bliss independence and Loewe additivity models. Greco et al. 4 have discussed these two reference models in detail. Conceptually, the Loewe additivity model focuses on dose reduction and the Bliss independence model focuses on treatment effect enhancement. The two reference models handle the same question from two different perspectives. The Bliss independence model has been criticized for its potential to incorrectly claim synergy when two identical drugs are combined (i.e., the sham experiment). But in reality, ethical and economic constraints preclude sham testing of a combination of two identical drugs to evaluate synergy in a clinical setting. Furthermore, we find that Bliss independence is legitimately derived from the complete additivity of probability theory 5 and serves well as a reasonable reference model. Suppose two drugs, A and B, both inhibit tumor growth: drug A at dose a inhibits a percent of tumor growth and drug B at dose b inhibits b percent of tumor growth. If two drugs work independently, the combined percentage inhibition can be predicted using the complete additivity of probability theory as = + (1) a b a b. 1 MedImmune LLC, Gaithersburg, MD, USA Abbvie INC, North Chicago, IL, USA * These authors contributed equally to this work. Received Oct 7, 013, and in revised form Nov 6, 013. Accepted for publication Jan 8, 014. Corresponding Author: Wei Zhao, Non-clinical Biostatistics Group, 1 MedImmune Way, Gaithersburg, MD 0878, USA. Zhaow@MedImmune.com
2 818 Journal of Biomolecular Screening 19(5) The observed combined percentage inhibition O is then compared with. Typically, if O >, the combination treatment is thought to be more efficacious than expected; if O <, the combination treatment is worse than expected; and if O =, the combination is equal to a simple addition of two separate drugs. More concisely, the three scenarios are summarized as O > = < Synergy Independent. Antagonism Typically, the comparison is examined at each dose combination. Average percentage inhibition is usually used when replicates are available and a conclusion can be drawn by strictly following equations (1) and (). But performing tests repetitively at all combination doses becomes a multiple testing problem, which easily leads to false-positive claims. Response surface methodology (RSM) is a well-established method to explore relationships between dose combinations and treatment effect in combination studies. Recently, a Loewe additivity based two-stage response surface model for a drug interaction index was developed. 6 The method gives a global view of synergistic effects across all drug combinations. However, we find in practice that the Loewe additivity based models work well only when monotherapy dose-response curves are well characterized through parametric models such as four-parameter logistic (4L) nonlinear regression curves. When dose-response curves are nonstandard or not available, we find that the Bliss independence based model provides a viable alternative. This is particularly important in high-throughput screening settings where large dose ranges are less practical. Even when large dose ranges are feasible for combination screening, nonstandard response curves compromise the reliability of the Loewe additivity model. In the following section, we adopt the two-stage framework to develop a response surface model based on Bliss independence. Methods We use a response surface model M( Γ a, b) to describe the difference between the observed percentage inhibition and the predicted percentage inhibition as () I = O ab, = M( Γ ab, ) + ε, (3) where ε is a random error that is normally distributed with mean 0 and variance σ, Г={γ 0, γ 1, γ, γ 3, γ 4, γ 5 } is a set of response surface model parameters. I is called the interaction index, an indicator for synergism. In this article, the response surface model we use is a quadratic polynomial function, M( Γ a, b) = γ + γ a+ γ b+ γ ab+ γ a + γ b If I is known, Г can be easily solved using the multiple linear regression method. Moving to the right side of the equation (3), we have O = ab, + M( Γ a, b) + ε. Since is a random term itself, its distribution will be estimated in the first stage and then be incorporated in the equation (3) to estimate parameters of the response surface model. In this way, the variance of the response surface model parameters will include the variance of O and the variance of. First Stage Model of the redicted ercentage Inhibition We estimate the predicted percentage inhibition,, in the first stage. The monotherapy percentage inhibition models at dose (a, b) can be written separately using simple linear regression models as = µ + e, = µ + e, a a a b b b where µ i (i = a, b) is the true percentage inhibition for drug A and B at dose (a, b) and e i is a normally distributed random error with mean 0 and variance σ i. Because negative inhibition values are often observed in real experiments, we model the percentage inhibition purposely using a Gaussian model instead of the more traditional logistic regression function to accommodate possible negative values. The similar modeling approach was adopted by other researchers as well. 7 The predicted percentage inhibition of the combination treatment can then be written as = µ a + µ b µµ a b + ea + eb µ aeb µ bea eaeb. (5) Since the expectations of all the terms with random errors are zero, the expectation of can be written as 5 (4) E( )= µ a + µ b µµ a b, (6) and the variance of and covariance between two combination doses, ab and a'b', can be written as var ( ab, )=( 1 µ b ) σ a + ( 1 µ a ) σ b + σσ a b, (7) ( )( ) = 1 µ b 1 µ b σa, if a a, b b cov (, a b, )= ( 1 µ a )( 1 µ a ) σb, if a a, b= b. (8) 0, if a a b b,
3 Zhao et al. 819 Figure 1. Monotherapy dose-response curves for the anti insulin-like growth factor 1 receptor (IGF1R) antibody and anti epidermal growth factor receptor (EGFR) antibody for the non small cell lung cancer (NSCLC) data. Second Stage Model to Calculate arameter Variance Conditional on the predicted percentage inhibition, the difference between O and is modeled using a response surface model. All parameters with a sign are estimated using statistical models. Following the two-stage paradigm, 6 the estimated variance covariance matrix of model parameters Γ can be written as ( ) + ( ( )) var Γ E var Γ, var E Γ ab ab,. ( )= ( ) The first term on the right-hand side of equation (9) is the mean variance of Γ assuming the predicted response is, and the second term is the variance of the expected Γ. roperly calculating var ( Γ ) is of critical importance in constructing the confidence interval of the interaction index. The bootstrap method is commonly used for this type of calculation. First, a random sample of is simulated from a multivariate normal distribution with mean and covariance matrix parameters calculated using equations (6), (7), and (8). Conditional on, response surface parameters Γ in equation (3) and var Γ ( ) in equation (9) are calculated using the linear model method. These steps are repeated for a number of times and then var ( Γ ) can be approximated by replacing expectation and variance with sample mean and sample variance in equation (9). var ( Γ ) roughly stabilizes after 50 iterations. Usually, the difference of var ( Γ ) between 50 and 10,000 iterations is within 15%, and the difference between 1000 and 10,000 repeats is within 5%. The 100(1 α)% confidence interval for interaction index I at any combination dose (a, b) can then be calculated using the following formula: ( 1 α/ 1 α/ ) CI = I z x var( Γ ) x, I + z x var( Γ ) x, (9) = ( ) where x 1, a, b, ab, a, b and z α/ is the 100(α/)th percentile of the standard normal distribution. α is the type I error rate, which is the probability to falsely claim the combination is synergistic when it is not. α=005. is commonly used as a benchmark error rate. Results Data for combinations studies reported here arise from in vitro combination experiments testing antibodies against two well-characterized and clinically validated oncology targets: the epidermal growth factor receptor (EGFR) and the insulin-like growth factor 1 receptor (IGF1R). Each of these targets has been shown to play a role in tumor biology. 8 Both are frequently coexpressed in tumor cells 9 and have been shown to be a part of the same cellular complexes using coimmunoprecipitation experiments. 10 Furthermore, cross-talk between the IGF1R and EGFR receptor has been shown to result in compensation and resistance during targeted inhibition of either receptor. 11 Finally, various preclinical studies have shown improved activity when both IGF1R and EGFR are inhibited concomitantly. 1,13 Given that anti-igf1r and anti-egfr antibodies have shown toxicity clinically, it is important to study the combined effects of anti-igf1r and anti-egfr treatment quantitatively. Of particular interest is the hypothesis that subtoxic doses of each agent might yield efficacy comparable to that seen with toxic doses separately because of synergism when tested in combination. These data are evaluated using the proposed model with a view toward predicting superior efficacy in combination than that observed when the same antibodies are dosed separately. In this experiment, both antibodies were tested at four doses (0.5, 5, 50, and 500 nm) in quadruplicate. Including monotherapy data, there are 96 data points in total. Figure 1 clearly shows that drug A does not follow a classic 4L
4 80 Journal of Biomolecular Screening 19(5) Table 1. Estimated arameters for the Non Small Cell Lung Cancer Data. γ 0 γ 1 γ γ 3 γ 4 γ dose-response curve, which precludes the use of Loewe additivity based models. Table 1 gives the estimated parameters of the response surface model. The 95% lower bound of the estimated interaction index is shown in Figure, and the contour plot with log 10 -transformed doses is shown in Figure 3. Strong synergistic interaction is seen at lower doses of both antibodies. Subsequent animal studies using the same antibodies in a xenograft model revealed synergistic activity arising from this target combination. 14 Discussion The Bliss independence based model has fewer restrictions than Loewe additivity based models. First, Loewe additivity models rely on accurately estimated doseresponse curves to support the calculation of the effective dose for a given response. When a 4L model is used for estimating a dose response, it is mandatory that the response has to fall between the estimated E min and E max parameters a result that is often not possible. When the data point is not between E min and E max, it has to be manually removed from the analysis, which is undesirable for statistical analysis. Second, the Loewe additivity model becomes unusable when a dose-response curve is not available or difficult to model. Third, the Loewe additivity model is far more computationally challenging than the Bliss independence model. When both methods have solutions, their results are very similar (comparisons not shown). The Bliss independence model presented in this article requires only a linear model technique, which is readily available in most software. Screening for effective combination drugs among hundreds of possible candidates is a challenging task. Those analytical methods without proper statistical modeling can easily lead to false decisions. The methodology introduced in this article rigorously considers the variances in both monotherapy and combination drug experiments and provides a practical way to integrate those variances into one comprehensive model. The confidence intervals constructed using this method have successfully helped us to identify synergistic regions of the test antibodies. Finally, it should be emphasized that most other methods provide only a simple score to quantify synergism. In contrast, the method reported here provides both a synergy score as well as a statistical confidence interval to qualify that synergy score. Figure. Estimated 95% lower confidence bound of interaction index based on Bliss Independence at all dose combinations. EGFR, epidermal growth factor receptor; IGF1R, insulin-like growth factor 1 receptor. Figure 3. Contour plot of interaction index for the anti insulin-like growth factor 1 receptor (IGF1R) antibody and anti epidermal growth factor receptor (EGFR) antibody combination for the non small cell lung cancer (NSCLC) data. The analysis was conducted using Windows R Code is available upon request.
5 Zhao et al. 81 Acknowledgment We thank David Stewart, Rachael Martin, and Rachael Eastwood in the informatics group for independently validating the program and developing a user friendly interface for internal use. Declaration of Conflicting Interests The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The authors received no financial support for the research, authorship, and/or publication of this article. References 1. Natarajan, M.; Lin, K. M.; Hsueh, R. C.; et al. A Global Analysis of Cross-Talk in a Mammalian Cellular Signalling Network. Nat. Cell Biol. 006, 8, Ramaswamy, S. Rational Design of Cancer-Drug Combinations. N. Engl. J. Med. 007, 357, Sun, T.; Aceto, N.; Meerbrey, K. L.; et al. Activation of Multiple roto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the TN1 hosphatase. Cell 011, 144, Greco, W. R.; Bravo, G.; arsons, J. C. The Search for Synergy: A Critical Review from a Response Surface erspective. harmacol. Rev. 1995, 47, Fisz, M. robability Theory and Mathematical Statistics; John Wiley: New ork, Zhao, W.; Zhang, L. J.; Zeng, L. M.; et al. A Two-Stage Response Surface Approach to Modeling Drug Interaction. Stat. Biopharm. Res. 01, 4, Novick, S. J. A Simple Test for Synergy for a Small Number of Combinations. Stat. Med. 013, 3, Belani, C..; Goss, G.; Blumenschein, G., Jr. Recent Clinical Developments and Rationale for Combining Targeted Agents in Non Small Cell Lung Cancer (NSCLC). Cancer Treat. Rev. 01, 38, Takahari, D.; amada,.; Okita, N. T.; et al. Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in atients with Colorectal Cancer. Oncology 009, 76, Riedemann, J.; Takiguchi, M.; Sohail, M.; et al. The EGF Receptor Interacts with the Type 1 IGF Receptor and Regulates Its Stability. Biochem. Biophys. Res. Commun. 007, 355, Jameson, M. J.; Beckler, A. D.; Taniguchi, L. E.; et al. Activation of the Insulin-Like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells. Mol. Cancer Ther. 011, 10, Dong, J.; Sereno, A.; Aivazian, D.; et al. A Stable IgG-Like Bispecific Antibody Targeting the Epidermal Growth Factor Receptor and the Type I Insulin-Like Growth Factor Receptor Demonstrates Superior Anti-Tumor Activity. mabs 011, 3, Galer, C. E.; Corey, C. L.; Wang, Z.; et al. Dual Inhibition of Epidermal Growth Factor Receptor and Insulin-Like Growth Factor Receptor I: Reduction of Angiogenesis and Tumor Growth in Cutaneous Squamous Cell Carcinoma. Head Neck 011, 33, Sachsenmeier, K. F.; Dimasi, N.; Huang, Q. H.; et al. The Avidity Hypothesis: Comparing Bi-specific and Monospecific Antibodies in re-clinical Oncology Models. latform resentation. American Association for Cancer Research Annual Meeting; Washington, DC, April 9, 013.
Lec 02: Estimation & Hypothesis Testing in Animal Ecology
Lec 02: Estimation & Hypothesis Testing in Animal Ecology Parameter Estimation from Samples Samples We typically observe systems incompletely, i.e., we sample according to a designed protocol. We then
More informationBiostatistics II
Biostatistics II 514-5509 Course Description: Modern multivariable statistical analysis based on the concept of generalized linear models. Includes linear, logistic, and Poisson regression, survival analysis,
More informationMEA DISCUSSION PAPERS
Inference Problems under a Special Form of Heteroskedasticity Helmut Farbmacher, Heinrich Kögel 03-2015 MEA DISCUSSION PAPERS mea Amalienstr. 33_D-80799 Munich_Phone+49 89 38602-355_Fax +49 89 38602-390_www.mea.mpisoc.mpg.de
More informationRunning head: NESTED FACTOR ANALYTIC MODEL COMPARISON 1. John M. Clark III. Pearson. Author Note
Running head: NESTED FACTOR ANALYTIC MODEL COMPARISON 1 Nested Factor Analytic Model Comparison as a Means to Detect Aberrant Response Patterns John M. Clark III Pearson Author Note John M. Clark III,
More informationA novel approach to estimation of the time to biomarker threshold: Applications to HIV
A novel approach to estimation of the time to biomarker threshold: Applications to HIV Pharmaceutical Statistics, Volume 15, Issue 6, Pages 541-549, November/December 2016 PSI Journal Club 22 March 2017
More informationChapter 11: Advanced Remedial Measures. Weighted Least Squares (WLS)
Chapter : Advanced Remedial Measures Weighted Least Squares (WLS) When the error variance appears nonconstant, a transformation (of Y and/or X) is a quick remedy. But it may not solve the problem, or it
More informationA Brief Introduction to Bayesian Statistics
A Brief Introduction to Statistics David Kaplan Department of Educational Psychology Methods for Social Policy Research and, Washington, DC 2017 1 / 37 The Reverend Thomas Bayes, 1701 1761 2 / 37 Pierre-Simon
More informationSection on Survey Research Methods JSM 2009
Missing Data and Complex Samples: The Impact of Listwise Deletion vs. Subpopulation Analysis on Statistical Bias and Hypothesis Test Results when Data are MCAR and MAR Bethany A. Bell, Jeffrey D. Kromrey
More informationBiomarkers in oncology drug development
Biomarkers in oncology drug development Andrew Stone Stone Biostatistics Ltd EFSPI Biomarkers and Subgroups June 2016 E: andrew@stonebiostatistics.com T: +44 (0) 7919 211836 W: stonebiostatistics.com available
More informationAnalysis of Vaccine Effects on Post-Infection Endpoints Biostat 578A Lecture 3
Analysis of Vaccine Effects on Post-Infection Endpoints Biostat 578A Lecture 3 Analysis of Vaccine Effects on Post-Infection Endpoints p.1/40 Data Collected in Phase IIb/III Vaccine Trial Longitudinal
More informationChapter 1. Introduction
Chapter 1 Introduction 1.1 Motivation and Goals The increasing availability and decreasing cost of high-throughput (HT) technologies coupled with the availability of computational tools and data form a
More informationAn Introduction to Bayesian Statistics
An Introduction to Bayesian Statistics Robert Weiss Department of Biostatistics UCLA Fielding School of Public Health robweiss@ucla.edu Sept 2015 Robert Weiss (UCLA) An Introduction to Bayesian Statistics
More informationNEW METHODS FOR SENSITIVITY TESTS OF EXPLOSIVE DEVICES
NEW METHODS FOR SENSITIVITY TESTS OF EXPLOSIVE DEVICES Amit Teller 1, David M. Steinberg 2, Lina Teper 1, Rotem Rozenblum 2, Liran Mendel 2, and Mordechai Jaeger 2 1 RAFAEL, POB 2250, Haifa, 3102102, Israel
More informationMark J. Anderson, Patrick J. Whitcomb Stat-Ease, Inc., Minneapolis, MN USA
Journal of Statistical Science and Application (014) 85-9 D DAV I D PUBLISHING Practical Aspects for Designing Statistically Optimal Experiments Mark J. Anderson, Patrick J. Whitcomb Stat-Ease, Inc., Minneapolis,
More informationQuantitative Evaluation of Edge Detectors Using the Minimum Kernel Variance Criterion
Quantitative Evaluation of Edge Detectors Using the Minimum Kernel Variance Criterion Qiang Ji Department of Computer Science University of Nevada Robert M. Haralick Department of Electrical Engineering
More informationIntroduction. We can make a prediction about Y i based on X i by setting a threshold value T, and predicting Y i = 1 when X i > T.
Diagnostic Tests 1 Introduction Suppose we have a quantitative measurement X i on experimental or observed units i = 1,..., n, and a characteristic Y i = 0 or Y i = 1 (e.g. case/control status). The measurement
More informationChallenges in Developing Learning Algorithms to Personalize mhealth Treatments
Challenges in Developing Learning Algorithms to Personalize mhealth Treatments JOOLHEALTH Bar-Fit Susan A Murphy 01.16.18 HeartSteps SARA Sense 2 Stop Continually Learning Mobile Health Intervention 1)
More informationBayesian Dose Escalation Study Design with Consideration of Late Onset Toxicity. Li Liu, Glen Laird, Lei Gao Biostatistics Sanofi
Bayesian Dose Escalation Study Design with Consideration of Late Onset Toxicity Li Liu, Glen Laird, Lei Gao Biostatistics Sanofi 1 Outline Introduction Methods EWOC EWOC-PH Modifications to account for
More informationAssessing drug synergy in combination therapies. Adam Palmer, Ph.D. Laboratory of Systems Pharmacology Harvard Medical School
Assessing drug synergy in combination therapies Adam Palmer, Ph.D. Laboratory of Systems Pharmacology Harvard Medical School Outline Introduction Pharmacokinetic and pharmacodynamic drug interactions Drug
More information1 Introduction. st0020. The Stata Journal (2002) 2, Number 3, pp
The Stata Journal (22) 2, Number 3, pp. 28 289 Comparative assessment of three common algorithms for estimating the variance of the area under the nonparametric receiver operating characteristic curve
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative
More informationClinical trial design issues and options for the study of rare diseases
Clinical trial design issues and options for the study of rare diseases November 19, 2018 Jeffrey Krischer, PhD Rare Diseases Clinical Research Network Rare Diseases Clinical Research Network (RDCRN) is
More informationAddendum: Multiple Regression Analysis (DRAFT 8/2/07)
Addendum: Multiple Regression Analysis (DRAFT 8/2/07) When conducting a rapid ethnographic assessment, program staff may: Want to assess the relative degree to which a number of possible predictive variables
More informationCertificate Courses in Biostatistics
Certificate Courses in Biostatistics Term I : September December 2015 Term II : Term III : January March 2016 April June 2016 Course Code Module Unit Term BIOS5001 Introduction to Biostatistics 3 I BIOS5005
More informationCOMPARING SEVERAL DIAGNOSTIC PROCEDURES USING THE INTRINSIC MEASURES OF ROC CURVE
DOI: 105281/zenodo47521 Impact Factor (PIF): 2672 COMPARING SEVERAL DIAGNOSTIC PROCEDURES USING THE INTRINSIC MEASURES OF ROC CURVE Vishnu Vardhan R* and Balaswamy S * Department of Statistics, Pondicherry
More informationConfidence Intervals On Subsets May Be Misleading
Journal of Modern Applied Statistical Methods Volume 3 Issue 2 Article 2 11-1-2004 Confidence Intervals On Subsets May Be Misleading Juliet Popper Shaffer University of California, Berkeley, shaffer@stat.berkeley.edu
More informationTwo-stage Methods to Implement and Analyze the Biomarker-guided Clinical Trail Designs in the Presence of Biomarker Misclassification
RESEARCH HIGHLIGHT Two-stage Methods to Implement and Analyze the Biomarker-guided Clinical Trail Designs in the Presence of Biomarker Misclassification Yong Zang 1, Beibei Guo 2 1 Department of Mathematical
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationMOST: detecting cancer differential gene expression
Biostatistics (2008), 9, 3, pp. 411 418 doi:10.1093/biostatistics/kxm042 Advance Access publication on November 29, 2007 MOST: detecting cancer differential gene expression HENG LIAN Division of Mathematical
More informationBayesian meta-analysis of Papanicolaou smear accuracy
Gynecologic Oncology 107 (2007) S133 S137 www.elsevier.com/locate/ygyno Bayesian meta-analysis of Papanicolaou smear accuracy Xiuyu Cong a, Dennis D. Cox b, Scott B. Cantor c, a Biometrics and Data Management,
More informationDeconRNASeq: A Statistical Framework for Deconvolution of Heterogeneous Tissue Samples Based on mrna-seq data
DeconRNASeq: A Statistical Framework for Deconvolution of Heterogeneous Tissue Samples Based on mrna-seq data Ting Gong, Joseph D. Szustakowski April 30, 2018 1 Introduction Heterogeneous tissues are frequently
More informationNumerical Integration of Bivariate Gaussian Distribution
Numerical Integration of Bivariate Gaussian Distribution S. H. Derakhshan and C. V. Deutsch The bivariate normal distribution arises in many geostatistical applications as most geostatistical techniques
More informationCase Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company
Case Studies in Bayesian Augmented Control Design Nathan Enas Ji Lin Eli Lilly and Company Outline Drivers for innovation in Phase II designs Case Study #1 Pancreatic cancer Study design Analysis Learning
More informationEffective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development. Pantelis Vlachos.
Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development Pantelis Vlachos Cytel Inc, Geneva Acknowledgement Joint work with Giacomo Mordenti, Grünenthal Virginie
More informationTHE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER GRADUATE COLLEGE A COMPARISON OF STATISTICAL ANALYSIS MODELING APPROACHES FOR STEPPED-
THE UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER GRADUATE COLLEGE A COMPARISON OF STATISTICAL ANALYSIS MODELING APPROACHES FOR STEPPED- WEDGE CLUSTER RANDOMIZED TRIALS THAT INCLUDE MULTILEVEL CLUSTERING,
More informationMultivariate Bioequivalence
Multivariate Bioequivalence S h i t a l A g a w a n e, S a n j u k t a R o y P h U S E 2013 S t r e a m : S t a t i s t i c s a n d P h a r m a c o k i n e t i c s S P 0 4 PhUSE 2013 Disclaimer Any views
More informationIDENTIFICATION OF OUTLIERS: A SIMULATION STUDY
IDENTIFICATION OF OUTLIERS: A SIMULATION STUDY Sharifah Sakinah Syed Abd Mutalib 1 and Khlipah Ibrahim 1, Faculty of Computer and Mathematical Sciences, UiTM Terengganu, Dungun, Terengganu 1 Centre of
More informationCombining Risks from Several Tumors Using Markov Chain Monte Carlo
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Environmental Protection Agency Papers U.S. Environmental Protection Agency 2009 Combining Risks from Several Tumors
More informationPSYCHOLOGY IAS MAINS: QUESTIONS TREND ANALYSIS
VISION IAS www.visionias.wordpress.com www.visionias.cfsites.org www.visioniasonline.com Under the Guidance of Ajay Kumar Singh ( B.Tech. IIT Roorkee, Director & Founder : Vision IAS ) PSYCHOLOGY IAS MAINS:
More informationFundamental Clinical Trial Design
Design, Monitoring, and Analysis of Clinical Trials Session 1 Overview and Introduction Overview Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics, University of Washington February 17-19, 2003
More informationBayesian and Frequentist Approaches
Bayesian and Frequentist Approaches G. Jogesh Babu Penn State University http://sites.stat.psu.edu/ babu http://astrostatistics.psu.edu All models are wrong But some are useful George E. P. Box (son-in-law
More informationConfounding by indication developments in matching, and instrumental variable methods. Richard Grieve London School of Hygiene and Tropical Medicine
Confounding by indication developments in matching, and instrumental variable methods Richard Grieve London School of Hygiene and Tropical Medicine 1 Outline 1. Causal inference and confounding 2. Genetic
More informationCitation for published version (APA): Ebbes, P. (2004). Latent instrumental variables: a new approach to solve for endogeneity s.n.
University of Groningen Latent instrumental variables Ebbes, P. IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationDiscussion Meeting for MCP-Mod Qualification Opinion Request. Novartis 10 July 2013 EMA, London, UK
Discussion Meeting for MCP-Mod Qualification Opinion Request Novartis 10 July 2013 EMA, London, UK Attendees Face to face: Dr. Frank Bretz Global Statistical Methodology Head, Novartis Dr. Björn Bornkamp
More informationUNIVERSITY of PENNSYLVANIA CIS 520: Machine Learning Midterm, 2016
UNIVERSITY of PENNSYLVANIA CIS 520: Machine Learning Midterm, 2016 Exam policy: This exam allows one one-page, two-sided cheat sheet; No other materials. Time: 80 minutes. Be sure to write your name and
More informationSimple Linear Regression the model, estimation and testing
Simple Linear Regression the model, estimation and testing Lecture No. 05 Example 1 A production manager has compared the dexterity test scores of five assembly-line employees with their hourly productivity.
More informationA STATISTICAL PATTERN RECOGNITION PARADIGM FOR VIBRATION-BASED STRUCTURAL HEALTH MONITORING
A STATISTICAL PATTERN RECOGNITION PARADIGM FOR VIBRATION-BASED STRUCTURAL HEALTH MONITORING HOON SOHN Postdoctoral Research Fellow ESA-EA, MS C96 Los Alamos National Laboratory Los Alamos, NM 87545 CHARLES
More information14. Linear Mixed-Effects Models for Data from Split-Plot Experiments
14. Linear Mixed-Effects Models for Data from Split-Plot Experiments opyright c 219 Dan Nettleton (Iowa State University) 14. Statistics 51 1 / 3 Start with a Field Field opyright c 219 Dan Nettleton (Iowa
More informationEmpirical assessment of univariate and bivariate meta-analyses for comparing the accuracy of diagnostic tests
Empirical assessment of univariate and bivariate meta-analyses for comparing the accuracy of diagnostic tests Yemisi Takwoingi, Richard Riley and Jon Deeks Outline Rationale Methods Findings Summary Motivating
More informationJ2.6 Imputation of missing data with nonlinear relationships
Sixth Conference on Artificial Intelligence Applications to Environmental Science 88th AMS Annual Meeting, New Orleans, LA 20-24 January 2008 J2.6 Imputation of missing with nonlinear relationships Michael
More informationBayesian Estimation of a Meta-analysis model using Gibbs sampler
University of Wollongong Research Online Applied Statistics Education and Research Collaboration (ASEARC) - Conference Papers Faculty of Engineering and Information Sciences 2012 Bayesian Estimation of
More informationThe Impact of Continuity Violation on ANOVA and Alternative Methods
Journal of Modern Applied Statistical Methods Volume 12 Issue 2 Article 6 11-1-2013 The Impact of Continuity Violation on ANOVA and Alternative Methods Björn Lantz Chalmers University of Technology, Gothenburg,
More informationDetection Theory: Sensitivity and Response Bias
Detection Theory: Sensitivity and Response Bias Lewis O. Harvey, Jr. Department of Psychology University of Colorado Boulder, Colorado The Brain (Observable) Stimulus System (Observable) Response System
More informationMathematical Microbiologists: Why we have to return to our square roots to uncover uncertainty (of measurement) in Quantitative PCR (qpcr)
Mathematical Microbiologists: Why we have to return to our square roots to uncover uncertainty (of measurement) in Quantitative PCR (qpcr) J. Ian Stuart George Zahariadis Marina Salvadori Objectives 1.
More informationA Bayesian Nonparametric Model Fit statistic of Item Response Models
A Bayesian Nonparametric Model Fit statistic of Item Response Models Purpose As more and more states move to use the computer adaptive test for their assessments, item response theory (IRT) has been widely
More informationBayesian Nonparametric Methods for Precision Medicine
Bayesian Nonparametric Methods for Precision Medicine Brian Reich, NC State Collaborators: Qian Guan (NCSU), Eric Laber (NCSU) and Dipankar Bandyopadhyay (VCU) University of Illinois at Urbana-Champaign
More informationEC352 Econometric Methods: Week 07
EC352 Econometric Methods: Week 07 Gordon Kemp Department of Economics, University of Essex 1 / 25 Outline Panel Data (continued) Random Eects Estimation and Clustering Dynamic Models Validity & Threats
More informationExperimental Design for Immunologists
Experimental Design for Immunologists Hulin Wu, Ph.D., Dean s Professor Department of Biostatistics & Computational Biology Co-Director: Center for Biodefense Immune Modeling School of Medicine and Dentistry
More informationAppendix III Individual-level analysis
Appendix III Individual-level analysis Our user-friendly experimental interface makes it possible to present each subject with many choices in the course of a single experiment, yielding a rich individual-level
More informationStudy Guide for the Final Exam
Study Guide for the Final Exam When studying, remember that the computational portion of the exam will only involve new material (covered after the second midterm), that material from Exam 1 will make
More informationA Case Study: Two-sample categorical data
A Case Study: Two-sample categorical data Patrick Breheny January 31 Patrick Breheny BST 701: Bayesian Modeling in Biostatistics 1/43 Introduction Model specification Continuous vs. mixture priors Choice
More informationMultiple trait model combining random regressions for daily feed intake with single measured performance traits of growing pigs
Genet. Sel. Evol. 34 (2002) 61 81 61 INRA, EDP Sciences, 2002 DOI: 10.1051/gse:2001004 Original article Multiple trait model combining random regressions for daily feed intake with single measured performance
More informationThe questions are changing in early phase cancer clinical trials: Opportunities for novel statistical designs
The questions are changing in early phase cancer clinical trials: Opportunities for novel statistical designs Elizabeth Garrett-Mayer, PhD Associate Professor Director of Biostatistics, Hollings Cancer
More informationProblem set 2: understanding ordinary least squares regressions
Problem set 2: understanding ordinary least squares regressions September 12, 2013 1 Introduction This problem set is meant to accompany the undergraduate econometrics video series on youtube; covering
More informationTreatment effect estimates adjusted for small-study effects via a limit meta-analysis
Treatment effect estimates adjusted for small-study effects via a limit meta-analysis Gerta Rücker 1, James Carpenter 12, Guido Schwarzer 1 1 Institute of Medical Biometry and Medical Informatics, University
More informationDecision Making in Confirmatory Multipopulation Tailoring Trials
Biopharmaceutical Applied Statistics Symposium (BASS) XX 6-Nov-2013, Orlando, FL Decision Making in Confirmatory Multipopulation Tailoring Trials Brian A. Millen, Ph.D. Acknowledgments Alex Dmitrienko
More informationDescribe what is meant by a placebo Contrast the double-blind procedure with the single-blind procedure Review the structure for organizing a memo
Business Statistics The following was provided by Dr. Suzanne Delaney, and is a comprehensive review of Business Statistics. The workshop instructor will provide relevant examples during the Skills Assessment
More informationMemorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center Memorial Sloan-Kettering Cancer Center, Dept. of Epidemiology & Biostatistics Working Paper Series Year 2007 Paper 14 On Comparing the Clustering of Regression Models
More informationMATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS
MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS DR. RACHEL E. LAING*, OLIVIER LESUEUR*, STAN HOPKINS AND DR. SEAN X. HU MAY 2012 Recent advances in oncology, such
More informationNew Challenges: Model-based Dose Finding in the Era of Targeted Agents
New Challenges: Model-based Dose Finding in the Era of Targeted Agents Elizabeth Garrett-Mayer, PhD 1 Cody Chiuzan, PhD 2 1 Hollings Cancer Center Department of Public Health Sciences Medical University
More informationThe SAGE Encyclopedia of Educational Research, Measurement, and Evaluation Multivariate Analysis of Variance
The SAGE Encyclopedia of Educational Research, Measurement, Multivariate Analysis of Variance Contributors: David W. Stockburger Edited by: Bruce B. Frey Book Title: Chapter Title: "Multivariate Analysis
More informationCalibrating Time-Dependent One-Year Relative Survival Ratio for Selected Cancers
ISSN 1995-0802 Lobachevskii Journal of Mathematics 2018 Vol. 39 No. 5 pp. 722 729. c Pleiades Publishing Ltd. 2018. Calibrating Time-Dependent One-Year Relative Survival Ratio for Selected Cancers Xuanqian
More informationTWISTED SURVIVAL: IDENTIFYING SURROGATE ENDPOINTS FOR MORTALITY USING QTWIST AND CONDITIONAL DISEASE FREE SURVIVAL. Beth A.
TWISTED SURVIVAL: IDENTIFYING SURROGATE ENDPOINTS FOR MORTALITY USING QTWIST AND CONDITIONAL DISEASE FREE SURVIVAL by Beth A. Zamboni BS Statistics, University of Pittsburgh, 1997 MS Biostatistics, Harvard
More informationInvestigating the robustness of the nonparametric Levene test with more than two groups
Psicológica (2014), 35, 361-383. Investigating the robustness of the nonparametric Levene test with more than two groups David W. Nordstokke * and S. Mitchell Colp University of Calgary, Canada Testing
More informationSCHOOL OF MATHEMATICS AND STATISTICS
Data provided: Tables of distributions MAS603 SCHOOL OF MATHEMATICS AND STATISTICS Further Clinical Trials Spring Semester 014 015 hours Candidates may bring to the examination a calculator which conforms
More informationCenter for Advanced Studies in Measurement and Assessment. CASMA Research Report
Center for Advanced Studies in Measurement and Assessment CASMA Research Report Number 39 Evaluation of Comparability of Scores and Passing Decisions for Different Item Pools of Computerized Adaptive Examinations
More informationASSESSING LONG-TERM BENEFITS OF IMMUNOTHERAPY BASED ON EARLY TUMOR ASSESSMENT DATA
ASSESSING LONG-TERM BENEFITS OF IMMUNOTHERAPY BASED ON EARLY TUMOR ASSESSMENT DATA PRALAY MUKHOPADHYAY AstraZeneca, Gaithersburg, USA XUEKUI ZHANG University of Victoria, Victoria, Canada Disclosures Pralay
More informationSurvival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer
Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer Jayashree Kalpathy-Cramer PhD 1, William Hersh, MD 1, Jong Song Kim, PhD
More informationVarious performance measures in Binary classification An Overview of ROC study
Various performance measures in Binary classification An Overview of ROC study Suresh Babu. Nellore Department of Statistics, S.V. University, Tirupati, India E-mail: sureshbabu.nellore@gmail.com Abstract
More informationMISSING DATA AND PARAMETERS ESTIMATES IN MULTIDIMENSIONAL ITEM RESPONSE MODELS. Federico Andreis, Pier Alda Ferrari *
Electronic Journal of Applied Statistical Analysis EJASA (2012), Electron. J. App. Stat. Anal., Vol. 5, Issue 3, 431 437 e-issn 2070-5948, DOI 10.1285/i20705948v5n3p431 2012 Università del Salento http://siba-ese.unile.it/index.php/ejasa/index
More informationBiostatistics Primer
BIOSTATISTICS FOR CLINICIANS Biostatistics Primer What a Clinician Ought to Know: Subgroup Analyses Helen Barraclough, MSc,* and Ramaswamy Govindan, MD Abstract: Large randomized phase III prospective
More informationProgress in Risk Science and Causality
Progress in Risk Science and Causality Tony Cox, tcoxdenver@aol.com AAPCA March 27, 2017 1 Vision for causal analytics Represent understanding of how the world works by an explicit causal model. Learn,
More informationStill important ideas
Readings: OpenStax - Chapters 1 13 & Appendix D & E (online) Plous Chapters 17 & 18 - Chapter 17: Social Influences - Chapter 18: Group Judgments and Decisions Still important ideas Contrast the measurement
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationBasic concepts and principles of classical test theory
Basic concepts and principles of classical test theory Jan-Eric Gustafsson What is measurement? Assignment of numbers to aspects of individuals according to some rule. The aspect which is measured must
More informationA Comparison of Several Goodness-of-Fit Statistics
A Comparison of Several Goodness-of-Fit Statistics Robert L. McKinley The University of Toledo Craig N. Mills Educational Testing Service A study was conducted to evaluate four goodnessof-fit procedures
More informationDynamic Outlier Algorithm Selection for Quality Improvement and Test Program Optimization
Dynamic Outlier Algorithm Selection for Quality Improvement and Test Program Optimization Authors: Paul Buxton Paul Tabor 5/21/04 Purpose Outliers and quality improvement Outliers and test program optimization
More informationA Biostatistics Applications Area in the Department of Mathematics for a PhD/MSPH Degree
A Biostatistics Applications Area in the Department of Mathematics for a PhD/MSPH Degree Patricia B. Cerrito Department of Mathematics Jewish Hospital Center for Advanced Medicine pcerrito@louisville.edu
More informationA Comparison of Robust and Nonparametric Estimators Under the Simple Linear Regression Model
Nevitt & Tam A Comparison of Robust and Nonparametric Estimators Under the Simple Linear Regression Model Jonathan Nevitt, University of Maryland, College Park Hak P. Tam, National Taiwan Normal University
More informationOptimal dose selection considering both toxicity and activity data; plateau detection for molecularly targeted agents
Optimal dose selection considering both toxicity and activity data; plateau detection for molecularly targeted agents Maria-Athina Altzerinakou1,2,3 and Xavier Paoletti3,1,2 1. CESP OncoStat, Inserm, Villejuif,
More informationReadings: Textbook readings: OpenStax - Chapters 1 13 (emphasis on Chapter 12) Online readings: Appendix D, E & F
Readings: Textbook readings: OpenStax - Chapters 1 13 (emphasis on Chapter 12) Online readings: Appendix D, E & F Plous Chapters 17 & 18 Chapter 17: Social Influences Chapter 18: Group Judgments and Decisions
More informationBayesian Joint Modelling of Benefit and Risk in Drug Development
Bayesian Joint Modelling of Benefit and Risk in Drug Development EFSPI/PSDM Safety Statistics Meeting Leiden 2017 Disclosure is an employee and shareholder of GSK Data presented is based on human research
More informationA Survey of Techniques for Optimizing Multiresponse Experiments
A Survey of Techniques for Optimizing Multiresponse Experiments Flavio S. Fogliatto, Ph.D. PPGEP / UFRGS Praça Argentina, 9/ Sala 402 Porto Alegre, RS 90040-020 Abstract Most industrial processes and products
More informationInternational Journal on Future Revolution in Computer Science & Communication Engineering ISSN: Volume: 4 Issue:
Application of the Variance Function of the Difference Between two estimated responses in regulating Blood Sugar Level in a Diabetic patient using Herbal Formula Karanjah Anthony N. School of Science Maasai
More informationBias in regression coefficient estimates when assumptions for handling missing data are violated: a simulation study
STATISTICAL METHODS Epidemiology Biostatistics and Public Health - 2016, Volume 13, Number 1 Bias in regression coefficient estimates when assumptions for handling missing data are violated: a simulation
More informationBREAST CANCER EPIDEMIOLOGY MODEL:
BREAST CANCER EPIDEMIOLOGY MODEL: Calibrating Simulations via Optimization Michael C. Ferris, Geng Deng, Dennis G. Fryback, Vipat Kuruchittham University of Wisconsin 1 University of Wisconsin Breast Cancer
More informationUNLOCKING VALUE WITH DATA SCIENCE BAYES APPROACH: MAKING DATA WORK HARDER
UNLOCKING VALUE WITH DATA SCIENCE BAYES APPROACH: MAKING DATA WORK HARDER 2016 DELIVERING VALUE WITH DATA SCIENCE BAYES APPROACH - MAKING DATA WORK HARDER The Ipsos MORI Data Science team increasingly
More information10-1 MMSE Estimation S. Lall, Stanford
0 - MMSE Estimation S. Lall, Stanford 20.02.02.0 0 - MMSE Estimation Estimation given a pdf Minimizing the mean square error The minimum mean square error (MMSE) estimator The MMSE and the mean-variance
More information